SCHEMBL6802167

SCHEMBL6802167

O=C(Nc1ccc(C(=O)N[C@H](CO)Cc2ccccc2)cn1)c1ccc2ccccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DEGS1 O15121 1/20 0.57
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
KMT2A Q03164 1/20 0.56
PIN1 Q13526 8/20 0.55
ROCK2 O75116 4/20 0.51
ROCK1 Q13464 3/20 0.51
RPS6KA5 O75582 1/20 0.51
RPS6KA4 O75676 1/20 0.51
PRKACA P17612 1/20 0.51
MAPK1 P28482 1/20 0.51
GSK3A P49840 1/20 0.51
GSK3B P49841 1/20 0.51
IRAK1 P51617 1/20 0.51
PRKX P51817 1/20 0.51
PRKG1 Q13976 1/20 0.51
PKN2 Q16513 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
SGK2 Q9HBY8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6802171 1.00 DEGS1 (0.57) DEGS1MEN1NPC1RAB9AKMT2A
SCHEMBL6793788 0.84 DEGS1 (0.56) DEGS1MEN1NPC1RAB9AKMT2A
SCHEMBL6793785 0.84 DEGS1 (0.56) DEGS1MEN1NPC1RAB9AKMT2A
SCHEMBL7789870 0.84 PIN1 (0.60) DEGS1MEN1NPC1RAB9AKMT2A
SCHEMBL7789871 0.84 PIN1 (0.60) DEGS1MEN1NPC1RAB9AKMT2A
SCHEMBL7782138 0.82 NPC1 (0.59) MEN1NPC1RAB9AKMT2APIN1
SCHEMBL7786980 0.79 NR1H4 (0.65) PIN1ROCK2ROCK1RPS6KA5RPS6KA4
SCHEMBL6799566 0.78 PIN1 (0.52) MEN1NPC1RAB9AKMT2APIN1
SCHEMBL6799561 0.78 PIN1 (0.52) MEN1NPC1RAB9AKMT2APIN1
SCHEMBL6801212 0.78 DEGS1 (0.75) DEGS1MEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use ABBOTT GMBH & CO. KG (DE) 2004-05-20 US disclosed
US-6630493-B1 Inhibitors of capain enzymes useful for the treatment of ischemias of the heart, the kidney or of central nervous system (e.g. \"stroke\"), inflammations, muscular dystrophy, cataracts of the eyes, Alzheimer's disease etc. BASF AKTIENGESELLSCHAFT (DE) 2003-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use CAPN1, CAPNS1, CAPN2 DEGS1 3477/4885MEN1 4075/4885NPC1 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.